2017 American Transplant Congress
Outcomes and Risk Factors for Graft Loss: Lessons Learned from More Than 1,056 Pediatric Kidney tx at a Single Center.
Aim:To study outcomes and risk factors for graft loss in > 1056 pediatric renal tx.Methods:We studied outcomes by immunosuppression era: I) 1963-83 (ALG, AZA and…2017 American Transplant Congress
Effect of Everolimus-Based Immunosuppressive Regimen on New Onset of Diabetes After Kidney Transplantation – A 24 Month Subanalysis from the ELEVATE Study.
1ELEVATE Study Group, Oslo, Norway; 2Novartis Pharma AG, Basel, Switzerland
Purpose: New onset diabetes after transplantation (NODAT) is a common metabolic complication which affects long-term patient survival and graft outcomes. Most of the immunosuppressive drugs…2017 American Transplant Congress
Evolution of Lipid Profile and Major Adverse Cardiac Events in Kidney Transplant Recipients Converted from Calcineurin Inhibitor to Everolimus: 24-Month Subanalysis from Elevate Study.
1ELEVATE Study Group, Berlin, Germany; 2Novartis Pharma AG, Basel, Switzerland
PURPOSE: Posttransplant (post-Tx) lipid abnormalities may increase risk of cardiovascular (CV) events in kidney transplant recipients (KTxR). Previous analysis from ELEVATE (NCT01114529) study confirmed that…2017 American Transplant Congress
A Phase-Two, Randomised, Placebo-Controlled Trial: Belimumab in Renal Transplantation Targets Naïve, Activated Memory and Antibody Producing B Cells Whilst Sparing Regulatory B Cells.
This phase 2, double-blind, randomised controlled study (BEL114424) explores the safety and potential efficacy of addition of belimumab to standard of care in renal transplantation…2017 American Transplant Congress
Tacrolimus Suppresses Calcineurin Activity and Ca2+ Influx Age-Specifically.
Immunosenescence is impacting alloimmunity and outcomes after organ transplantation. Age-dependent effects of immunosuppressants, however, have not been tested sufficiently. Here, we tested the effects of…2017 American Transplant Congress
Tofacitinib-Loaded Solid Lipid Nanoparticles Inhibits Dendritic Cell Antigen Presenting Functions and Achieve Selective In Vivo Targeting.
BackgroundComplications from long-term use of calcineurin inhibitors are a major concern for transplant patients. To develop CNI-free therapies, we investigated an innovative drug delivery method…2017 American Transplant Congress
Infections and Outcomes in Renal Transplantation Patients Using Alemtuzumab for Induction Immunosuppression: Preliminary Results.
Surgery, University of Toledo College of Medicine, Toledo, OH
Introduction: Alemtuzumab (Ale) is a monoclonal antibody targeting CD52+ lympocytes. We sought to determine the impact of Ale immunodepletion, with steroid freedom for low risk…2017 American Transplant Congress
Immunosuppressive Therapy and Acute Rejection in Combined Heart and Kidney Transplantation.
University of Louisville, Louisville
Background. This study evaluated the management of immunosuppressive therapy and the incidence of acute heart rejection within 1 year from concomitant heart-kidney transplantation (cHTKx) compared…2017 American Transplant Congress
In Vitro Optimisation of the Immunotherapeutic Effects of Umbilical Cord Derived MSC.
Mesenchymal stromal cells (MSC) possess immunomodulatory properties and are low immunogenic, which are both important for their development into an effective cellular immunotherapy after organ…2017 American Transplant Congress
Population Pharmacokinetic Profiling of Tacrolimus in Renal Transplant Recipients (RTRs) Taking Diltiazem.
Background: Over the past 6 years we have prospectively used pharmacokinetic (PK) profiling of Tacrolimus (TAC) in “stable” RTR's to individualise future dosing. This study…
- « Previous Page
- 1
- …
- 84
- 85
- 86
- 87
- 88
- …
- 138
- Next Page »